VanEck Video Gaming and eSports ETF vs Merck & Co., Inc. — how do they compare? VanEck Video Gaming and eSports ETF trades at $100.11 (market cap $248.06M), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 1416.1× VanEck Video Gaming and eSports ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while VanEck Video Gaming and eSports ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Video Gaming and eSports ETF for 66 Days and Merck & Co., Inc. for 98 Days on average.
| ESPO | MRK | |
|---|---|---|
Market Cap | $248.06M | $351.28B |
Volume | 13,622 | 7,969,665 |
Sector | Sector/Thematic | Health |
52-Week High | $116.66 | $156.43 |
52-Week Low | $85.25 | $82.49 |
Typical Hold Time | 66 Days | 98 Days |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Signals from Pluang's Aura AI — not financial advice
ESPO stock shows strong technical momentum, gaining 2.87% to $100.11 with a bullish moving average signal. The stock trades near resistance levels at $98-$99 while maintaining support at $97. Technical indicators show mixed signals with neutral RSI readings but positive ADX momentum. Fundamental data remains limited pending updated financial disclosures.
The technical setup suggests near-term upside potential if resistance levels are breached, though limited fundamental visibility warrants caution. Key risks include lack of recent financial data and market volatility. Investors require updated earnings reports and analyst coverage for proper valuation assessment before establishing positions.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →